Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | SLC13A5 | Q86YT5 | 8/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HMGCR | P04035 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL27574347 | 0.84 | ALDH1A1 (0.56) | ALDH1A1KDM4ESLC13A5MAPTLMNA | |
| SCHEMBL8444150 | 0.83 | ALDH1A1 (0.50) | ALDH1A1KDM4ESLC13A5MAPTLMNA | |
| SCHEMBL30384961 | 0.79 | ALDH1A1 (0.60) | ALDH1A1KDM4ESLC13A5MAPTLMNA | |
| Citric Acid SCHEMBL4292973 | 0.79 | ALDH1A1 (0.60) | ALDH1A1KDM4ESLC13A5MAPTLMNA | |
| Citric Acid SCHEMBL2238478 | 0.79 | ALDH1A1 (0.60) | ALDH1A1KDM4ESLC13A5MAPTLMNA | |
| SCHEMBL72953 | 0.79 | ALDH1A1 (0.60) | ALDH1A1KDM4ESLC13A5MAPTLMNA | |
| SCHEMBL284647 | 0.78 | ALDH1A1 (0.50) | ALDH1A1LMNATSHRALOX15MEN1 | |
| Citric Acid SCHEMBL2490516 | 0.78 | ALDH1A1 (0.58) | ALDH1A1KDM4ESLC13A5MAPTLMNA | |
| Ammonia Solution, Strong SCHEMBL29179739 | 0.78 | ALDH1A1 (0.58) | ALDH1A1KDM4ESLC13A5MAPTLMNA | |
| SCHEMBL433131 | 0.78 | ALDH1A1 (0.58) | ALDH1A1KDM4ESLC13A5MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238155-A1 | CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL DISORDERS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-08-05 | — | — | US | disclosed |
| WO-2020081723-A1 | CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL DISORDERS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238155-A1 | CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL DISORDERS | PYGL, HMOX2, MB | MEN1 2174/4885ALDH1A1 976/4885KDM4E 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.